Hydrocortisone Shortage: What Providers and Prescribers Need to Know in 2026

Hydrocortisone oral tablets have remained on the FDA drug shortage database since April 2020, making this one of the most persistent supply disruptions affecting endocrinology, rheumatology, and primary care practices. For patients with primary adrenal insufficiency (PAI), congenital adrenal hyperplasia (CAH), or secondary adrenal insufficiency, hydrocortisone is not a convenience — it is a life-sustaining therapy.

This briefing provides prescribers with a current assessment of the hydrocortisone supply landscape, therapeutic substitution guidance, dose conversion protocols, and tools to help patients access their medication.

Current Supply Landscape

As of 2026, hydrocortisone oral tablets (5 mg, 10 mg, 20 mg) remain officially listed as "Currently in Shortage" by the FDA. The shortage originated in 2020 when Amneal Pharmaceuticals discontinued all HC tablet presentations. Greenstone (Pfizer's generic subsidiary) placed its product on allocation. The primary manufacturers remaining in the market are Pfizer (Cortef branded and Greenstone generic) and Vensun Pharmaceuticals.

The Solu-Cortef (hydrocortisone sodium succinate) injectable shortage that began in 2023 was largely resolved by late 2025. Providers should confirm current availability with their institution's pharmacy department, as supply can fluctuate.

Clinical Implications of the Shortage

The shortage creates several significant clinical challenges:

Adrenal crisis risk: Patients with PAI or CAH who cannot fill prescriptions face life-threatening risk. Abrupt discontinuation of hydrocortisone in these patients can precipitate an adrenal crisis.

Dosing precision challenges: Pediatric patients with CAH often require very small, precise doses (e.g., 2.5 mg or 5 mg) that are difficult to replicate with alternative corticosteroids.

Physiological replacement specificity: Hydrocortisone's short half-life (8-12 hours) and combined glucocorticoid/mineralocorticoid activity make it uniquely suited for physiological replacement. Longer-acting alternatives may not replicate the circadian cortisol rhythm.

Insurance and formulary barriers: Brand-name Cortef, which maintains better availability, faces insurance barriers including step therapy requirements and higher copays.

Therapeutic Substitution Protocols

When hydrocortisone is unavailable, the following substitutions may be considered, with appropriate dose conversion and patient counseling:

Glucocorticoid Equivalence Table

Hydrocortisone 20 mg (reference) | Half-life: 8-12 hrs | Relative potency: 1 | Mineralocorticoid activity: Moderate

Prednisone 5 mg | Half-life: 12-36 hrs | Relative potency: 4 | Mineralocorticoid: Minimal

Prednisolone 5 mg | Half-life: 12-36 hrs | Relative potency: 4 | Mineralocorticoid: Minimal

Methylprednisolone 4 mg | Half-life: 12-36 hrs | Relative potency: 5 | Mineralocorticoid: None

Dexamethasone 0.75 mg | Half-life: 18-36 hrs | Relative potency: 25-30 | Mineralocorticoid: None

Key Prescribing Considerations When Substituting

Mineralocorticoid replacement: Hydrocortisone has significant mineralocorticoid activity at physiological doses. When switching to prednisone, prednisolone, or methylprednisolone (which have minimal mineralocorticoid activity), patients with PAI may need concurrent fludrocortisone (Florinef) added or doses adjusted.

Sick day rules: Counsel patients that sick day protocols (stress dosing — typically doubling or tripling the daily dose during illness or injury) still apply, adjusted to the equivalent dose of the alternative corticosteroid.

Pediatric patients with CAH: Strongly consider compounded hydrocortisone before switching to an alternative corticosteroid. Precise low-dose administration is critical in pediatric CAH management. Consult with a pediatric endocrinologist.

Circadian rhythm: Hydrocortisone is typically given 2-3 times daily to mimic the natural cortisol rhythm. Longer-acting alternatives like prednisone given once daily do not replicate this rhythm, which may impact patient symptoms and outcomes.

When Brand-Name Cortef Is the Right Answer

For most patients, the simplest solution is to prescribe brand-name Cortef rather than switching drug classes. Cortef has generally maintained better availability than generics throughout the shortage. Prescribing strategies to improve insurance coverage:

Write "Dispense as Written" (DAW) on the prescription with a clinical justification citing the active FDA shortage of generic hydrocortisone

Submit a prior authorization citing the shortage and medical necessity of consistent manufacturer/formulation

Refer patients to the HealthWell Foundation patient assistance program, which may help cover Cortef costs

Tools and Resources for Providers

FDA Drug Shortage Database: accessdata.fda.gov — for official shortage status updates

ASHP Drug Shortage Resource Center — clinical guidance and current shortage bulletins

National Adrenal Diseases Foundation (NADF) — patient resources and shortage advocacy updates

medfinder for Providers — Direct patients to medfinder to check real-time pharmacy availability near them

The hydrocortisone shortage is a manageable clinical challenge, but it requires proactive planning. By maintaining familiarity with substitution protocols, leveraging brand-name Cortef when appropriate, and directing patients to availability tools, prescribers can minimize treatment disruptions for their most vulnerable patients.